ECSP003413A - THERAPY FOR CHRONIC MYELOCITIC LEUKEMIA - Google Patents
THERAPY FOR CHRONIC MYELOCITIC LEUKEMIAInfo
- Publication number
- ECSP003413A ECSP003413A ECSP003413A ECSP003413A EC SP003413 A ECSP003413 A EC SP003413A EC SP003413 A ECSP003413 A EC SP003413A EC SP003413 A ECSP003413 A EC SP003413A
- Authority
- EC
- Ecuador
- Prior art keywords
- myelocitic
- leukemia
- chronic
- therapy
- effective amount
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 102100040018 Interferon alpha-2 Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010079944 Interferon-alpha2b Proteins 0.000 abstract 1
- 230000002559 cytogenic effect Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen los métodos para tratar pacientes que no recibieron tratamiento alguno asi como pacientes que experimentaron algún tratamiento que padecen de CML, para lograr al menos, una respuesta citogénica parcial; los métodos incluyen administrar una cantidad terapéuticamente efectiva de interferón-alfa modificado con PEG por ejemplo, interferón alfa 2b modificado con PEG como monoterapia o asociado con una cantidad terapéuticamente efectiva de Ara-C.Methods of treating patients who received no treatment as well as patients who underwent treatment with CML are described to achieve at least a partial cytogenic response; methods include administering a therapeutically effective amount of PEG modified interferon-alpha eg, PEG modified interferon alpha 2b as monotherapy or associated with a therapeutically effective amount of Ara-C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003413 ECSP003413A (en) | 2000-04-05 | 2000-04-05 | THERAPY FOR CHRONIC MYELOCITIC LEUKEMIA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003413 ECSP003413A (en) | 2000-04-05 | 2000-04-05 | THERAPY FOR CHRONIC MYELOCITIC LEUKEMIA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003413A true ECSP003413A (en) | 2000-11-24 |
Family
ID=42041042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003413 ECSP003413A (en) | 2000-04-05 | 2000-04-05 | THERAPY FOR CHRONIC MYELOCITIC LEUKEMIA |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003413A (en) |
-
2000
- 2000-04-05 EC ECSP003413 patent/ECSP003413A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021876A1 (en) | COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO | |
| BR9809425A (en) | Alpha interferon-polyethylene glycol conjugates for infection therapy | |
| AR021226A1 (en) | COMBINATORY THERAPY WITH RIBAVIRINA-INTERFERON ALFA TO ERADICATE DETECTABLE HCV-RNA IN THOSE PATIENTS WHO PRESENT INFECTION WITH CHRONIC HEPATITIS C | |
| PL365285A1 (en) | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs | |
| ES2162393T3 (en) | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION. | |
| NO20032027L (en) | Effective anti-tumor treatments | |
| BRPI0415249A (en) | combination therapy for hcv infection | |
| BRPI0409865A (en) | intravenous injection of non-neurotoxic plasminogen activators for stroke attack treatment | |
| BR0016831A (en) | Therapeutic composition and contact lens impregnated by it | |
| DK1030667T3 (en) | Use of mirtazapine in the manufacture of a medicament for the treatment of sleep apnea | |
| AR022116A1 (en) | COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA | |
| SE0004101D0 (en) | New use | |
| CL2022002104A1 (en) | Treatment of coronavirus infection with lambda interferon | |
| ES2036560T3 (en) | A METHOD FOR PREPARING A SYNERGICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF HYPERTENSION. | |
| AR023390A1 (en) | THERAPY FOR CHRONIC MYELOCITIC LEUKEMIA | |
| BR0009644A (en) | Treatment of renal cell carcinoma | |
| CO5160259A1 (en) | INTERFERON ALFA PEGILADO IN THE THERAPY AGAINST HIV | |
| MXPA05007901A (en) | Hcv combination therapy. | |
| AR024537A1 (en) | SYNERGIC COMBINATION FOR THE TREATMENT OF VIRAL MEDIUMED DISEASES | |
| AR013498A1 (en) | USE OF IFN-ALPHA AND AMANTADINE FOR THE TREATMENT OF CHRONIC HEPATITIS C USE OF IFN-ALPHA | |
| DE60125377D1 (en) | TREATMENT OF HEPATITIS C WITH THYMOSINE, INTERFERON AND RIBAVIRIN | |
| PT1150981E (en) | THERAPEUTIC NUCLEOSIDAL COMPOSITION | |
| DK1311286T3 (en) | Treatment of hepatitis C with thymosin and pegylated interferon | |
| ECSP003373A (en) | HIV THERAPY | |
| WO2003059334A3 (en) | Gemcitabine in the treatment of smallpox |